Recursion Pharmaceuticals Correlations
| RXRX Stock | USD 5.02 0.27 5.10% |
The current 90-days correlation between Recursion Pharmaceuticals and Enveric Biosciences is 0.15 (i.e., Average diversification). The correlation of Recursion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Recursion Pharmaceuticals Correlation With Market
Weak diversification
The correlation between Recursion Pharmaceuticals and DJI is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Recursion Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Recursion |
Moving together with Recursion Stock
| 0.68 | WMT | Walmart Aggressive Push | PairCorr |
| 0.65 | JPM | JPMorgan Chase | PairCorr |
| 0.68 | DD | Dupont De Nemours | PairCorr |
Moving against Recursion Stock
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Recursion Stock performing well and Recursion Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Recursion Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ABSI | 5.26 | 0.18 | 0.01 | 0.00 | 5.47 | 16.40 | 36.32 | |||
| AFMD | 2.61 | (0.68) | 0.00 | (1.28) | 0.00 | 5.10 | 23.29 | |||
| SANA | 7.71 | 1.42 | 0.17 | 0.39 | 6.59 | 10.15 | 178.30 | |||
| RLAY | 4.19 | (0.54) | 0.00 | (0.34) | 0.00 | 6.27 | 26.72 | |||
| IMMX | 2.97 | (0.28) | 0.00 | (0.38) | 0.00 | 6.77 | 21.65 | |||
| CNSP | 6.93 | (1.29) | 0.00 | (1.61) | 0.00 | 12.10 | 81.40 | |||
| HEPA | 9.97 | (4.54) | 0.00 | (3.97) | 0.00 | 16.37 | 90.05 | |||
| FRLN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AVRO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| EFTR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Recursion Pharmaceuticals Corporate Management
| Christopher Gibson | CEO CoFounder | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Nathan Hatfield | Chief Officer | Profile |